<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00454883</url>
  </required_header>
  <id_info>
    <org_study_id>A1281159</org_study_id>
    <nct_id>NCT00454883</nct_id>
  </id_info>
  <brief_title>Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.</brief_title>
  <official_title>Treatment Of Manic Or Mixed Episodes Of Up To Moderate Severity In Patients With Bipolar Disorder And Schizoaffective Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective
      disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Method: Consecutive patient sampling. Patients were included in the study in consecutive
      manner if they fulfilled the inclusion criteria and any of the exclusion criteria were not
      present.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical global impression</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recording of extrapyramidal symptoms</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in manic symptoms over course of treatment</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of disease</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">379</enrollment>
  <condition>Affective Psychosis, Bipolar</condition>
  <condition>Mania</condition>
  <condition>Manic-Depressive Psychosis</condition>
  <arm_group>
    <arm_group_label>1 cohort of patients treated with ziprasidone</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ziprasidone</intervention_name>
    <description>Ziprasidone 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment.</description>
    <arm_group_label>1 cohort of patients treated with ziprasidone</arm_group_label>
    <other_name>Geodon, Zeldox</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients were identified in in- and outpatients settings (university departments,
        hospital wards, outpatients clinics, daily psychiatric hospitals)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Manic and mixed episodes of up to moderate severity in patients with Type I and II
             bipolar disorder and schizoaffective disorder; either first diagnosed or repeated
             episodes

        Exclusion Criteria:

          -  Hypersensitivity to ziprasidone

          -  prolonged QTc interval

          -  coadministration with substances that are prolonging the QTc interval

          -  recent acute MI, cardiac failure, patients with arrhythmias treated with class IA or
             III medicaments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>Slovakia</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281159&amp;StudyName=Non-interventional%20study%20of%20ziprasidone%20in%20the%20treatment%20of%20bipolar%20and%20schizoaffective%20disorders.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2007</study_first_submitted>
  <study_first_submitted_qc>March 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2007</study_first_posted>
  <last_update_submitted>June 30, 2015</last_update_submitted>
  <last_update_submitted_qc>June 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety of ziprasidone, efficacy of ziprasidone, manic episodes in bipolar disorder, mixed episodes in bipolar disorder, schizoaffective disorder.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Affective Disorders, Psychotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

